Though interest in robotics is high in Europe, much of the commercial opportunity will likely fall to two small US companies who are just now aggressively spreading the gospel of robotics through affiliations with minimally-invasive surgery pioneers. That's not to say that European companies are standing idly by: Germany's Maquet is pushing forward with an orthopedic robot. Many obstacles to adoption remain for robots, but the high cost of these units may not be as much of a problem as might be expected. The goal--and challenge--for robotic companies and their clinical advocates: to firmly establish computer-assisted surgery as an important new platform and clinical advance in surgical practice.
by David Cassak
Part II of a two part-series
Join thousands of industry professionals who rely on In Vivo for daily insights
Already a subscriber?
Despite the ability to initiate clinical trials quickly and having strong manufacturing capacity, Chinese companies are facing multiple challenges in the obesity space.
Big pharma plans to invest billions of dollars in US manufacturing to avoid tariffs proposed by the Trump Administration. However, the implementation of these plans may be delayed due to regulatory complexities and rising costs from tariffs, potentially impacting drug prices for consumers.
S2 Xpeed is driving the rapid growth of medtech and hardware start-ups in Europe. Operating under a "sweat equity" model, the program helps early-stage companies move from prototype to manufacturing readiness in exchange for equity.
Crystal Qin has led LaNova Medicines’ swift rise in the biotech world through strategic partnerships and innovative R&D, highlighted by a record deal with big pharma.
The whirlwind back-and-forth on US tariffs and Robert F. Kennedy jr.’s plans to deregulate health care have become all-preoccupying, but the National Academy of Medicine was first to set out President Trump’s health administration priorities.
Mikkel Wandahl Pederson, CEO and chief scientific officer at Commit Biologics, discussed the company’s mission to harness the powerful complement system for the treatment of serious diseases.
Phenomix Science presented new data at Digestive Disease Week 2025 showing its machine learning-assisted genetic risk score can predict nausea and side effects from GLP-1 receptor agonists, aiding personalized obesity treatment.
